Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro - PubMed (original) (raw)
Comparative Study
Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro
P D Holtom et al. J Orthop Res. 2000 Sep.
Abstract
We studied the inhibitory effects of the fluoroquinolones levofloxacin, ciprofloxacin, and trovafloxacin on growth and extracellular matrix mineralization in MC3T3-E1 osteoblast-like cell cultures. Levofloxacin had the least inhibitory effect on cell growth, with a 50% inhibitory concentration of approximately 80 microg/ml at 48 and 72 hours. Ciprofloxacin had an intermediate degree of inhibition, with a 50% inhibitory concentration of 40 microg/ml at 48 and 72 hours. Trovafloxacin exerted a profound inhibitory effect on cell growth, with a 50% inhibitory concentration of 0.5 microg/ml, lower than clinically achievable serum levels. The decreased cell counts with up to 2.5 microg/ml of trovafloxacin and with up to 40 microg/ml of ciprofloxacin were not associated with decreased rates of 5-bromo-2'-deoxyuridine incorporation per cell. Alatrovafloxacin, the L-alanyl-l-alanine prodrug of trovafloxacin, exerted effects on proliferation and 5-bromo-2'-deoxyuridine incorporation similar to those of the parent compound. The quinolones evaluated also inhibited extracellular matrix mineralization by MC3T3-E1 cells. Treatment of confluent cultures with trovafloxacin, ciprofloxacin, or levofloxacin resulted in strong inhibition of calcium deposition, as determined on day 14 by alizarin red staining and biochemical analysis. The effect was apparent with 2.5-5 microg/ml of each of the three antibiotics tested and progressively increased to more than a 90% decline in the calcium/protein ratio with 20-40 microg/ml antibiotic concentration. Further in vivo studies are advocated to evaluate the relevance of the in vitro cytotoxicity reported here to bone healing in orthopaedic patients.
Similar articles
- Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro.
Miclau T, Edin ML, Lester GE, Lindsey RW, Dahners LE. Miclau T, et al. J Orthop Res. 1998 Jul;16(4):509-12. doi: 10.1002/jor.1100160417. J Orthop Res. 1998. PMID: 9747794 - Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN, Kohlhepp SJ, Slama KA, Grunkemeier G, Lewis G, Dworkin RJ, Slaughter SE, Leggett JE. Gilbert DN, et al. Antimicrob Agents Chemother. 2001 Mar;45(3):883-92. doi: 10.1128/AAC.45.3.883-892.2001. Antimicrob Agents Chemother. 2001. PMID: 11181375 Free PMC article. - In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
Isenberg HD, Alperstein P, France K. Isenberg HD, et al. Diagn Microbiol Infect Dis. 1998 Oct;32(2):115-8. doi: 10.1016/s0732-8893(98)00078-9. Diagn Microbiol Infect Dis. 1998. PMID: 9823535 - Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
Ernst ME, Ernst EJ, Klepser ME. Ernst ME, et al. Am J Health Syst Pharm. 1997 Nov 15;54(22):2569-84. doi: 10.1093/ajhp/54.22.2569. Am J Health Syst Pharm. 1997. PMID: 9397218 Review. - Seizures associated with fluoroquinolones.
Kushner JM, Peckman HJ, Snyder CR. Kushner JM, et al. Ann Pharmacother. 2001 Oct;35(10):1194-8. doi: 10.1345/aph.10359. Ann Pharmacother. 2001. PMID: 11675843 Review.
Cited by
- Insights on the properties of levofloxacin-adsorbed Sr- and Mg-doped calcium phosphate powders.
Marques CF, Matos AC, Ribeiro IA, Gonçalves LM, Bettencourt A, Ferreira JM. Marques CF, et al. J Mater Sci Mater Med. 2016 Jul;27(7):123. doi: 10.1007/s10856-016-5733-2. Epub 2016 Jun 14. J Mater Sci Mater Med. 2016. PMID: 27300006 - Intra-wound vancomycin powder for the eradication of periprosthetic joint infection after debridement and implant exchange: experimental study in a rat model.
Wei J, Tong K, Zhou S, Wang H, Wen Y, Chen L. Wei J, et al. BMC Microbiol. 2021 Dec 7;21(1):333. doi: 10.1186/s12866-021-02399-5. BMC Microbiol. 2021. PMID: 34876010 Free PMC article. - Management of open fractures.
Blease R, Kanlić E. Blease R, et al. Bosn J Basic Med Sci. 2005 Nov;5(4):14-21. doi: 10.17305/bjbms.2005.3224. Bosn J Basic Med Sci. 2005. PMID: 16351592 Free PMC article. Review. - Prophylactic intrawound application of vancomycin powder in instrumented spinal fusion surgery.
Kim HS, Lee SG, Kim WK, Park CW, Son S. Kim HS, et al. Korean J Spine. 2013 Sep;10(3):121-5. doi: 10.14245/kjs.2013.10.3.121. Epub 2013 Sep 30. Korean J Spine. 2013. PMID: 24757472 Free PMC article. - Evidence-Based Recommendations for Local Antimicrobial Strategies and Dead Space Management in Fracture-Related Infection.
Metsemakers WJ, Fragomen AT, Moriarty TF, Morgenstern M, Egol KA, Zalavras C, Obremskey WT, Raschke M, McNally MA; Fracture-Related Infection (FRI) consensus group. Metsemakers WJ, et al. J Orthop Trauma. 2020 Jan;34(1):18-29. doi: 10.1097/BOT.0000000000001615. J Orthop Trauma. 2020. PMID: 31464858 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources